Taro Completes Acquisition of Alchemee
February 28 2022 - 6:19PM
Business Wire
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) today
announced the completion of its acquisition of Alchemee, formerly
The Proactiv Company (TPC), from Galderma. The acquisition includes
Alchemee’s business and assets worldwide, including the Proactiv®
brand.
“This acquisition demonstrates Taro’s commitment to
strengthening our position in the over-the-counter dermatology
space,” said Uday Baldota, Taro’s CEO. “In addition to adding
Proactiv® to our product portfolio, we are also gaining the
omni-channel marketing capabilities and expertise of the Alchemee
team. We look forward to working with them to continue Proactiv®’s
legacy as an iconic brand synonymous with acne care.”
Alchemee's flagship brand, Proactiv, is America’s #1 acne
routine1 and has been used and trusted by millions around the world
for more than 25 years.
“We are excited for Alchemee and its marquee brand, Proactiv®,
to join the expansive Taro portfolio of prescription and
over-the-counter dermatology products,” said Shannon Pappas, Global
Head of Alchemee. “This strategic move further positions Alchemee
for continued growth in the skincare space.”
- Based on 2021 FDM/Specialty retail sales.
About Taro
Taro Pharmaceutical Industries Ltd. is a multinational,
science-based pharmaceutical company, dedicated to meeting the
needs of its customers through the discovery, development,
manufacturing and marketing of the highest quality healthcare
products. For further information on Taro Pharmaceutical Industries
Ltd., please visit the Company’s website at www.taro.com.
Forward-Looking Statements
Some of the information contained in this press release may
contain forward-looking statements. Readers are cautioned that any
such forward-looking statements are not guarantees of future
performance and involve risks and uncertainties, and that actual
results may differ materially from those in the forward-looking
statements as a result of various factors. Neither Taro nor
Alchemee has any obligation to publicly update or revise any
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220228006187/en/
Taro William J. Coote VP, Chief Financial Officer (914)
345-9001 William.Coote@taro.com
Taro Pharmaceutical Indu... (NYSE:TARO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Taro Pharmaceutical Indu... (NYSE:TARO)
Historical Stock Chart
From Apr 2023 to Apr 2024